Sepsis syndrome is linked with a systemic inflammatory response syndrome (SIRS). This severe inflammation is associated with an immune suppression as illustrated by the reduced capacity of circulating leukocytes to produce cytokines in response to in vitro activation. Non-infectious SIRS such as trauma, burn, hemorrhage or major surgery is also associated with a suppression of the immune system. This phenomenon has been recently termed CARS for compensatory anti-inflammatory response syndrome. We report in vitro experiments which suggest that a well-known anti-inflammatory cytokine, namely IL-10, may, in certain experimental conditions, prime the leukocytes finally leading to an increased cytokine production. We discuss the relevance of this in vitro model to the in vivo situations where immune suppression is limited to the blood compartment (or the hematopoietic organs) whereas, in inflammatory foci within the tissues, cytokine production is increased. Our data suggest that IL-10 may be a causative agent of concomitantly occurring SIRS and CARS.
References
1.
Christou NVHost defense mechanism in surgical patients: a correlation study of the delayed hypersensitivity skin test response, granulocyte function and sepsis. Can J Surg1985; 28: 39—49.
2.
Keane R., Birmingham W., Shatney C., Winchurch R., Munster A.Prediction of sepsis in the multitraumatic patients by assays of lymphocyte responsiveness. Surg Gynecol Obstet1983; 156: 163—167.
3.
Maturana P, Puente, Miranda D., Sepulveda C., Wolf ME, Mosnaim ADNatural killer cell activity in patients with septic shock. J Crit Care1991; 6: 42—45.
4.
Stephan RN, Saizawa M., Conrad PJ, Dean RE, Geha AS, Chaudry IHDepressed antigen presentation function and membrane interleukin-1 activity of peritoneal macrophages after laparotomy. Surgery1987; 102: 147—154.
5.
Luger A., Graf H., Schwarz HP, Stummvoll HK, Luger TADecreased serum interleukin-1 activity and monocytes interleukin-1 production in patients with fatal sepsis. Crit Care Med1986; 14: 458—461.
6.
Helminen M.Interleukin-1 production from peripheral blood monocytes in septic infections in children. Scand J Infect Dis1991; 23: 607—611.
7.
Muñoz C., Carlet J., Fitting C., Misset B., Bleriot JP, Cavaillon J-M.Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest1991; 88: 1747—1754.
8.
Cavaillon J-M., Muñoz C., Marty C. et al. Cytokine production by monocytes from patients with sepsis syndrome and by endotoxin-tolerant monocytes. In: Levin J, Alving CR, Munford RS, Stütz PL, eds. Bacterial Endotoxin: Recognition and Effector Mechanisms, Amsterdam: Elsevier, 1993; 275—284.
9.
Sekatrian JC , Yee J., Christou NVReduced tumor necrosis factorα production in lipopolysaccharide-treated whole blood from patients in the intensive care unit. Arch Surg1994; 129: 187—192.
10.
Ertel W., Kremer J., Kenney J. et al. Down-regulation of proinflammatory cytokine release in whole blood from septic patients. Blood1995; 85: 1341—1347.
11.
Döcke WD, Randow F., Syrbe U. et al. Monocyte deactivation in septic patients: restoration by IFNγ treatment. Nat Med1997; 3: 678—681.
12.
Marchant A. , Alegre M., Hakim A. et al. Clinical and biological significance of interleukin-10 plasma levels in patients with septic shock. J Clin Immunol1995; 15: 265—272.
13.
Ertel W., Keel M., Neidhardt R. et al. Inhibition of the defense system stimulating interleukin-12 interferon-γ pathway during critical illness. Blood1997; 89: 1612—1620.
14.
Van Deuren M., Van Der Ven-Jongekrijg H., Demacker Pnm et al. Differential expression of proinflammatory cytokines and their inhibitors during the course of meningococcal infections. J Infect Dis1994; 169: 157—161.
15.
Wood J., Rodrick M., O'Mahony J. et al. Inadequate interleukin 2 production. A fundamental immunological deficiency in patients with major burns. Ann Surg1984; 200: 311—320.
16.
Muret J., Marie C., Fitting C., Payen D., Cavaillon J-M.Sepsis and inflammation affect Th1 as well as Th2 cytokine production . Submitted.
17.
McCall CE, Grosso-Wilmoth LM, LaRue K., Guzman RN, Cousart SLTolerance to endotoxin-induced expression of the interleukin-1β gene in blood neutrophils of humans with the sepsis syndrome. J Clin Invest1993; 91: 853—861.
18.
Marie C., Muret J., Fitting C., Losser M-R., Payen D., Cavaillon J-M.Reduced ex vivo interleukin-8 production by neutrophils in septic and non-septic systemic inflammatory response syndrome. Blood1998; 91: 3439—3446.
19.
Marie C., Muret J., Fitting C., Payen D., Cavaillon J-M.IL-1ra production during infectious and non-infectious systemic inflammatory response syndrome. Submitted.
20.
Brandtzaeg P., Osnes L., vstebø R., Joø GB, Westwik AB, Kierulf P.Net inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target cell assay: identification of interleukin-10 as a major functional deactivator of human monocytes. J Exp Med1996; 184: 51—60.
21.
Randow F., Syrbe U., Meisel C., Krausch D., Zuckermann H., Platzer C., Volk H.Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor β. J Exp Med1995; 181: 1887—1892.
22.
Ertel W., Keel M., Steckholzer U., Ungethüm U., Trentz O.Interleukin-10 attenuates the release of pro-inflammatory cytokines but depresses splenocytes function in murine endotoxemia. Arch Surg1996; 131: 51—56.
23.
Ayala A., Knotts JB, Ertel W., Perrin MM, Morrison MH, Chaudry IHRole of interleukin 6 and transforming growth factor-beta in the induction of depressed splenocyte responses following sepsis. Arch Surg1993; 128: 89—94.
24.
Miller-Graziano CL, Szabo G., Griffey K., Mehta B., Kodys K., Catalano D.Role of elevated monocyte transforming growth factor β production in post-trauma immunosuppression . J Clin Immunol1991. 11: 95—102.
25.
Ayala A., Lehman DL, Herdon CD, Chaudry IHMechanism of enhanced susceptibility to sepsis following hemorrhage. Interleukin-10 suppression of T-cell response is mediated by eicosanoid-induced interleukin-4 release. Arch Surg1994; 129: 1172—1178.
26.
Marchant A., Devière J., Byl B., De Groote D, Vincent J., Goldman M.Interleukin-10 production during septicaemia. Lancet1994; 343: 707—708.
27.
Marie C., Cavaillon J-M., Losser M-R.Elevated levels of circulating transforming growth factor-β1 in patients with the sepsis syndrome. Ann Intern Med1996 ; 125: 520—521.
28.
Dehoux M., Philip I., Chollet-Martin S., Boutten A., Hvass U., Desmonts JM, Durand G.Early production of interleukin-10 during normothermic cardiopulmonary bypass . J Thorac Cardiovasc Surg1995; 110: 286—287.
29.
Cabié A., Fitting C., Farkas J-C. et al. Influence of surgery on in vitro cytokine production by human monocytes. Cytokine1992; 4: 576—580.
30.
Schinkel C., Zimmer S., Kremer JP et al. Comparative analysis of transcription and protein release of the inflammatory cytokines interleukin-1 beta (IL-1 beta) and interleukin-8 (IL-8) following major burn and mechanical trauma. Shock1995. 4: 241—246.
31.
Bone RC, Grodzin CJ, Balk RASepsis: a new hypothesis for pathogenesis of the disease process. Chest1997; 121: 235—243.
32.
Lin RY, Astiz ME, Saxon JC, Rackow ECAltered leukocyte immunophenotypes in septic shock. Studies of HLA-DR, CD11b, CD14, and IL-2R expression. Chest1993 ; 104: 847—853.
33.
Ertel W., Morrison MH, Ayala A., Dean R., Chaudry IHInterferon-γ attenuates hemorrhage-induced suppression of macrophage and splenocyte functions and decreases susceptibility to sepsis. Surgery1992; 111: 177—187.
34.
Polk HC, Cheadle, Livingston DH et al. A randomized prospective clinical trial to determine the efficacy of interferon-γ in severely injured patients. Am J Surg1992; 163: 191—196.
35.
Dries DJ, Jurkovich GJ, Maier RV et al. Effect of interferon-gamma on infection-related death in patients with severe injuries. A randomized, double-blind, placebo-controlled trial . Arch Surg1994; 129: 1031—1041.
36.
Levy EM, Alharbi SA, Grindlinger G., Black PHChanges in mitogen responsiveness lymphocytes subsets after traumatic injury: relation to development of sepsis. Clin Immunol Immunopathol1984; 32: 224—233.
37.
Jacobs RF, Tabor DR, Burks AW, Campbell GDElevated interleukin-1 release by human alveolar macrophages during adult respiratory distress syndrome. Am Rev Respir Dis1989; 140: 1686—1692.
38.
Fieren Mwja , Van Den Bemd GJ, Bonta ILEndotoxin-stimulated peritoneal macrophages obtained from continuous ambulatory peritoneal dialysis patients show an increased capacity to release interleukin-1β in vitro during infectious peritonitis . Eur J Clin Invest1990; 20: 453—457.
39.
Tsuchida M. , Watanabe H., Watanabe T. et al. Effect of cardiopulmonary bypass on cytokine release and adhesion molecule expression in alveolar macrophages . Am J Respir Crit Care Med1997; 156: 932—938.
40.
Rugtveit J. , Nilsen EM, Bakka A., Carlsen H., Brandtzaeg P., Scott H.Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease . Gastroenterology1997; 112: 1493—1505.
41.
40a Abid-Conguy M., Petit AF, Marie C., Fitting C., Cavaillon JMParadoxical priming effects of IL-10 on cytokine productioin. Int Immunol1999; 11: 689.
42.
Zheng XX, Steele AW, Nickerson PW, Steurer W., Steiger J., Strom TBAdministration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation. J Immunol1995; 154: 5590—5600.
43.
Qian SG, Li W., Li YP et al. Systemic administration of cellular interleukin-10 can exacerbate cardiac allograft rejection in mice. Transplantation1996; 62: 1709—1714.
44.
Li W., Lu L., Li Y. et al. High-dose cellular IL-10 exacerbates rejection and reverses effects of cyclosporine and tacrolimus in mouse cardiac transplantation. Transplant Proc1997; 29: 1081—1082.
45.
Rosenbaum JT , Angell E.Paradoxical effects of IL-10 in endotoxin-induced uveitis. J Immunol1995; 155: 4090—4094.
46.
Wogensen L. , Lee MS, Sarvetnick N.Production of interleukin-10 by islet cells accelerates immune-mediated destruction of β cells in nonobese diabetic mice. J Exp Med1994; 179: 1379—1384.
47.
Moritani M. , Yoshimoto K., Tashiro F. et al. Transgenic expression of IL-10 in pancreatic islet A cells accelerates autoimmune insulitis and diabetes in non-obese diabetic mice. Int Immunol1994; 6: 1927—1936.
48.
Berman RM, Suzuki T., Tahara H., Robbins PD, Narula SK, Lotze MTSystemic administration of cellular IL-10 induces an effective specific and long-lived immune response against established tumor in mice. J Immunol1996; 157: 231—238.
49.
Di Carlo E. , Coletti A., Modesti A., Giovarelli M., Forni G., Musiani P.Local release of interleukin-10 by transfected mouse adenocarcinoma cells exhibits pro- and anti-inflammatory activity and results in a delayed tumor rejection. Eur Cytokine Netw1998; 9: 61—68.
50.
Chernoff A. , Granowitz E., Shapiro L. et al. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses . J Immunol1995; 154: 5492—5499.
51.
Huhn RD, Radwanski E., O'Connell SM et al. Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. Blood1996; 87: 699—705.
52.
Cunha FQ, Moncada S., Liew FYInterleukin-10 (IL-10) inhibits the induction of nitric oxide synthase by interferon-gamma in murine macrophages. Biochem Biophys Res Commun1992; 182: 1155—1159.
53.
Fouqueray B. , Boutard V., Philippe C. et al. Mesangial cell-derived interleukin-10 modulates mesangial cell response to lipopolysaccharide. Am J Pathol1995; 147: 176—182.
54.
Pang G., Ortega M., Zighang R., Reeves G., Clancy R.Autocrine modulation of IL-8 production by sputum neutrophils in chronic bronchial sepsis. Am J Respir Crit Care Med1997; 155: 726—731.
